Neuromyelitis optics spectrum disorders of remitting stage Nervous System Diseases Neuromyelitis optics spectrum disorders of remitting stage
Conditions
Interventions
Participants are randomised to one of two groups using a computerised random number table.
Intervention group: Participants are treated with oral azathioprine at a dose of 2mg/Kg-D for three months i
Sponsors
Beijing Traditional Chinese Medical Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosis of neuromyelitis optics spectrum disorders in accordance with NMOSDs diagnostic criteria established by the international panel for NMO diagnosis (IPND) in 2015. 2. In remission stage (no acute progress, no corticosteroid therapy or immunoglobulin therapy, plasma exchange, stable condition without relapse signs) 3. Age of 18-75 years old 4. EDSS score less than 5 5. No other treatment with immunosuppressive drugs within 6 months or no other immunosuppressive drugs other than azathioprine 6. Provision of informed consent
Exclusion criteria
Exclusion criteria: 1. Oral azathioprine intolerant patients 2. History of severe allergies 3. Those who can not tolerate acupuncture 4. Clinically significant history of disease, blood disease, endocrine, metabolism, liver, lung, urinary system, nervous system, skin disease, other major primary disease and psychiatric disease 5. Malignant tumor 6. B type hepatitis 7. Pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disability is measured using the Expanded disability scale score at baseline, 3, 6 and 12 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. AQP4-IgG level is measured using cell transfection method at baseline and 3 months 2. Annual relapse rate is measured using computer formula at baseline, 3, 6 and 12 months | — |
Countries
China
Contacts
Public ContactChunchen Wang
Outcome results
None listed